NEOADJUVANT PD-1 BLOCKADE IN NSCLC

被引：1
|
作者：
Killock, David
机构：
[1] Nature Reviews Clinical Oncology,
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2018年 / 15卷 / 07期
关键词：
D O I：
10.1038/s41571-018-0032-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：404 / 404
页数：1
相关论文
共 50 条
  • [1] Neoadjuvant PD-1 blockade in NSCLC
    David Killock
    [J]. Nature Reviews Clinical Oncology, 2018, 15 : 404 - 404
  • [2] Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
    Gao, Shugeng
    Li, Ning
    Gao, Shunyu
    Xue, Qi
    Ying, Jianming
    Wang, Shuhang
    Tao, Xiuli
    Zhao, Jun
    Mao, Yousheng
    Wang, Bing
    Shao, Kang
    Lei, Wendong
    Wang, Dali
    Lv, Fang
    Zhao, Liang
    Zhang, Fan
    Zhao, Ziran
    Su, Kai
    Tan, Fengwei
    Gao, Yibo
    Sun, Nan
    Wu, Dawei
    Yu, Yue
    Ling, Yun
    Wang, Zhijie
    Duan, Chunjian
    Tang, Wei
    Zhang, Lei
    He, Shun
    Wu, Ning
    Wang, Jie
    He, Jie
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (05) : 816 - 826
  • [3] Combining chemotherapy with PD-1 blockade in NSCLC
    Mathew, Matthen
    Enzler, Thomas
    Shu, Catherine A.
    Rizvi, Naiyer A.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2018, 186 : 130 - 137
  • [4] Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC
    Rosner, Samuel
    Forde, Patrick M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (04) : 503 - 509
  • [5] Chemotherapy thorn PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLC
    Hendriks, Lizza E. L.
    Remon, Jordi
    Reck, Martin
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (04) : 499 - 502
  • [6] Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade
    Shuhang Wang
    Pei Yuan
    Beibei Mao
    Ning Li
    Jianming Ying
    Xiuli Tao
    Wei Tang
    Lei Zhang
    Xiao Geng
    Fan Zhang
    Qi Xue
    Lijia Wu
    Henghui Zhang
    Shugeng Gao
    Jie He
    [J]. npj Precision Oncology, 6
  • [7] Features in genomics and tumor immune microenvironment in NSCLC treated with neoadjuvant PD-1 blockade.
    Wang, Shuhang
    Li, Ning
    Mao, Beibei
    Ying, Jianming
    Tao, Xiuli
    Tang, Wei
    Zhang, Lei
    Geng, Xiao
    Zhang, Fan
    Xue, Qi
    Wu, Lijia
    Zhang, Henghui
    Gao, Shugeng
    He, Jie
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Peripheral T Cell Repertoire Evolution in Resectable NSCLC Treated with Neoadjuvant PD-1 Blockade
    Zhang, J.
    Ji, Z.
    Caushi, J.
    El Asmar, M.
    Anagnostou, V.
    Cottrell, T.
    Chan, H. Y.
    Guo, H.
    Merghoub, T.
    Chaft, J.
    Wolchok, J.
    Reuss, J.
    Marrone, K.
    Naidoo, J.
    Gabrielson, E.
    Taube, J.
    Brahmer, J.
    Velculescu, V.
    Zhao, N.
    Hellmann, M.
    Forde, P.
    Pardoll, D.
    Yegnasubramanian, S.
    Ji, H.
    Smith, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S293 - S294
  • [9] Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade
    Wang, Shuhang
    Yuan, Pei
    Mao, Beibei
    Li, Ning
    Ying, Jianming
    Tao, Xiuli
    Tang, Wei
    Zhang, Lei
    Geng, Xiao
    Zhang, Fan
    Xue, Qi
    Wu, Lijia
    Zhang, Henghui
    Gao, Shugeng
    He, Jie
    [J]. NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [10] PD-1 blockade in advanced NSCLC: A focus on pembrolizumab
    Peters, Solange
    Kerr, Keith M.
    Stahel, Rolf
    [J]. CANCER TREATMENT REVIEWS, 2018, 62 : 39 - 49
12345